Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNK3 | O14649 | 6/20 | 0.71 |
| ▸ | KCNK9 | Q9NPC2 | 5/20 | 0.71 |
| ▸ | PKM | P14618 | 1/20 | 0.70 |
| ▸ | SNCA | P37840 | 2/20 | 0.65 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.63 |
| ▸ | RAB9A | P51151 | 4/20 | 0.61 |
| ▸ | NPC1 | O15118 | 3/20 | 0.61 |
| ▸ | HPGD | P15428 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 4/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.56 |
| ▸ | UNG | P13051 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30440532 | 1.00 | KCNK3 (0.71) | KCNK3KCNK9PKMSNCASIRT1 | |
| SCHEMBL13917760 | 0.92 | PKM (0.59) | KCNK3KCNK9PKMSNCASIRT1 | |
| SCHEMBL15651385 | 0.90 | PKM (0.58) | KCNK3KCNK9PKMSNCASIRT1 | |
| SCHEMBL9454755 | 0.90 | HDAC1 (0.63) | KCNK3KCNK9PKMSNCASIRT1 | |
| SCHEMBL22543054 | 0.87 | SNCA (0.83) | KCNK3KCNK9PKMSNCASIRT1 | |
| SCHEMBL1663054 | 0.86 | KCNK3 (0.59) | KCNK3KCNK9PKMSNCASIRT1 | |
| SCHEMBL15652762 | 0.86 | KCNK3 (0.68) | KCNK3KCNK9PKMSNCAHPGD | |
| SCHEMBL15651930 | 0.86 | UNG (0.70) | KCNK3KCNK9PKMRAB9ANPC1 | |
| SCHEMBL15651539 | 0.86 | KMT2A (0.62) | KCNK3KCNK9PKMSNCARAB9A | |
| SCHEMBL2106756 | 0.86 | L3MBTL1 (0.71) | KCNK3KCNK9PKMRAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116239578-A | Piperazine dione ring compound, synthesis method thereof and application thereof in preparation of antitumor drugs | 中国海洋大学 | 2023-06-09 | — | — | CN | disclosed |
| US-9637491-B2 | Pyrazolo[4,3-D]pyrimidines as kinase inhibitors | ORIGENIS GMBH (DE) | 2017-05-02 | — | — | US | disclosed |
| US-20150266882-A1 | PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2015-09-24 | — | — | US | disclosed |
| WO-2014060112-A1 | PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2014-04-24 | — | — | WO | disclosed |
| WO-2009112615-A1 | PHARMACEUTICAL COMPOSITION FOR INHIBITING THE TRANSCRIPTION FACTOR INDUCIBLE BY HYPOXIA, MODULATORS OF PATHOLOGICAL PROCESSES OF ANGIOGENESIS, ONCOGENESIS, INFLAMMATION, APOPTOSIS, AND CELLULAR THERAPY | FUNDACIÓN DE LA COMUNIDAD VALENCIANA, CENTRO DE INVESTIGACIÓN PRINCIPE FELIPE (ES) | 2009-09-17 | — | — | WO | disclosed |
| EP-1165494-B1 | HSV PRIMASE INHIBITORS | BOEHRINGER INGELHEIM CA LTD (CA) | 2003-11-05 | — | — | EP | disclosed |
| EP-1165494-A2 | HSV PRIMASE INHIBITORS | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2002-01-02 | — | — | EP | disclosed |
| US-6323202-B1 | BENZAMIDE SUBSTITUTES WITH KETONE COMPOUNDS AS ENZYME INHIBITORS | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2001-11-27 | — | — | US | disclosed |
| WO-2000058270-A2 | HSV PRIMASE INHIBITORS | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2000-10-05 | — | — | WO | disclosed |
| US-5234946-A | Anticholesterol, antilipemic | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1993-08-10 | — | — | US | disclosed |
| EP-0318860-B1 | SUBSTITUTED ALKYLAMINE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1993-06-16 | — | — | EP | disclosed |
| EP-0318860-A2 | Substituted alkylamine derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1989-06-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150266882-A1 | PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS | LRRK2, MYLK2, MYLK | KCNK3 350/4885KCNK9 434/4885PKM 478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.